Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Kuo

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Thoracic Cancer|November 25, 2022
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from TaiwanJohn Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, et al.
Therapeutic Advances in Respiratory Disease|October 28, 2022
Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutationsPing-Chih Hsu, John Wen-Cheng Chang, Ching-Fu Chang, et al.
Cancers|October 27, 2022
Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer PatientsYan-Jei Tang, John Wen-Cheng Chang, Ching-Fu Chang, et al.
Thoracic Cancer|August 1, 2023
Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinibChen-Te Wu, Ping-Chih Hsu, John Wen-Cheng Chang, et al.
Anticancer Research|March 29, 2022
Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring <i>EGFR</i> MutationsChi-Han Chen, John Wen-Cheng Chang, Ching-Fu Chang, et al.
Targeted Oncology|July 27, 2019
Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of OsimertinibChih-Hsi Scott Kuo, Chi-Hsien Huang, Chien-Ying Liu, et al.
Thoracic Cancer|April 17, 2025
Baseline and changes in inflammatory parameters for patients with EGFR-mutated NSCLC treated with afatinibZi-Ting Chang, Ping-Chih Hsu, How-Wen Ko, et al.
BMC Cancer|March 25, 2021
A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failedChih-Hsi Scott Kuo, Pi-Hung Tung, Allen Chung-Cheng Huang, et al.
Thoracic Cancer|April 6, 2019
Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancerChih-Hsi Scott Kuo, Chin-Chou Wang, Yu-Chen Huang, et al.
Immunity, Inflammation and Disease|November 22, 2024
Correlation Between mRNA Expression of Activated Eosinophils and Air Pollutant Exposure in Patients With AsthmaTing-Yu Lin, Po-Jui Chang, Chun-Yu Lo, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Thoracic Cancer|November 25, 2022
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from TaiwanJohn Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, et al.
Therapeutic Advances in Respiratory Disease|October 28, 2022
Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutationsPing-Chih Hsu, John Wen-Cheng Chang, Ching-Fu Chang, et al.
Cancers|October 27, 2022
Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer PatientsYan-Jei Tang, John Wen-Cheng Chang, Ching-Fu Chang, et al.
Thoracic Cancer|August 1, 2023
Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinibChen-Te Wu, Ping-Chih Hsu, John Wen-Cheng Chang, et al.
Anticancer Research|March 29, 2022
Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring <i>EGFR</i> MutationsChi-Han Chen, John Wen-Cheng Chang, Ching-Fu Chang, et al.
Targeted Oncology|July 27, 2019
Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of OsimertinibChih-Hsi Scott Kuo, Chi-Hsien Huang, Chien-Ying Liu, et al.
Thoracic Cancer|April 17, 2025
Baseline and changes in inflammatory parameters for patients with EGFR-mutated NSCLC treated with afatinibZi-Ting Chang, Ping-Chih Hsu, How-Wen Ko, et al.
BMC Cancer|March 25, 2021
A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failedChih-Hsi Scott Kuo, Pi-Hung Tung, Allen Chung-Cheng Huang, et al.
Thoracic Cancer|April 6, 2019
Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancerChih-Hsi Scott Kuo, Chin-Chou Wang, Yu-Chen Huang, et al.
Immunity, Inflammation and Disease|November 22, 2024
Correlation Between mRNA Expression of Activated Eosinophils and Air Pollutant Exposure in Patients With AsthmaTing-Yu Lin, Po-Jui Chang, Chun-Yu Lo, et al.
Pageof 4